Neurodegeneration Research
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Neurodegenerative diseases are highly prevalent disorders for which the greatest risk factor is increasing age. The pathogenesis of these disorders is yet to be fully understood, and current research efforts are focused on elucidating the cellular and molecular mechanisms responsible, with the hope that drugs that prevent or reverse disease progression will be discovered. Three of the major neurodegenerative diseases are Alzheimer's disease, Parkinson's disease and Huntington's disease, which are discussed in this product guide. Research into these disorders has so far yielded few drugs that have proven effective in clinical trials, and many current therapies are targeted at attenuating disease symptoms, rather than disease progression.
Due to the prevalence of neurodegenerative diseases, they constitute a significant human, societal and economic burden. The global financial cost far outweighs other disorders such as stroke, musculoskeletal disease, heart disease or cancer. Given the aging population, the incidence of neurodegenerative disorders is predicted to rise; early diagnosis and effective treatment is of paramount importance, and these rely on a greater understanding of the mechanisms that underlie each disorder.
Included in this guide are key compounds used in the study of Alzheimer's, Parkinson's and Huntington's disease, as well as illustrative schematics of the molecular mechanisms thought to contribute to each disease. The use of small molecule inhibitors and antagonists to facilitate such research has helped delineate the pathways involved in these diseases, as well as providing a solid foundation for the development of future targeted therapeutics. Tocris provides an innovative range of high performance life science reagents for use in neurodegeneration research, equipping researchers with selective pharmacological tools for studying these disease pathways. A full product listing can be found on pages 24-33.
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Neurodegeneration Neurodegeneration is the progressive death of neurons in the brain that leads to a loss of structure and function. Alzheimer's, Parkinson's and Huntington's disease are the three major disorders that develop as a result of neurodegeneration, and will be discussed in this guide. Each disorder has characteristic symptoms in the early stages of the disease, such as the cognitive decline associated with the onset of Alzheimer's; a loss of motor control, which is often an early indicator of Parkinson's disease; or behavioral changes symptomatic of Huntington's disease. As we age, our susceptibility to these diseases increase, and it is thought that this may be due to an increased vulnerability of particular neuronal populations within defined areas of the brain. It is worth noting that approximately 10% of neurons die as a consequence of 'healthy', non-pathological aging; indeed, protein aggregates synonymous with Alzheimer's disease have also been observed in asymptomatic patients.
As a population ages, the prevalence of neurodegeneration is likely to increase. Effective treatments to prevent progression of neurodegenerative disorders are notably absent with no strong candidates currently on the horizon. Alzheimer's disease, the most prevalent neurodegenerative disease worldwide, was estimated to affect 35.6 million people in the world in 2010 and it is thought that the numbers of those affected will almost double every 20 years*, in line with an aging population.
The mechanisms that lead to neuronal cell death in neurodegenerative diseases are not well understood. However, it is believed that neurodegenerative diseases have common cellular and molecular mechanisms. Dysregulation of protein synthesis, degradation and transport, alongside hallmark features such as protein misfolding, accumulation into aggregates as well as inclusion body formation, are characteristic of all three diseases that will be covered in this guide. A recently identified mechanism applicable to all neurodegenerative diseases describes how cell death may occur: a build-up of misfolded proteins in the brain over-activates a natural defensive mechanism -the unfolded protein response -which switches off the production of new proteins. This effectively starves the neuron of the proteins it needs for normal function and triggers cell death. Researchers are targeting this mechanism by trying to block the 'off' switch in studies that may be a possible turning point for the treatment of all neurodegenerative diseases.
Neurons have machinery that helps defend against the build-up of misfolded and aggregated proteins. If chaperone proteins fail to induce proper folding, abnormal proteins can be targeted for degradation by attachment of polyubiquitin and targeting to the proteasome for degradation. Similarly, the autophagy/ lysosomal pathways are known to arbitrate between neuronal survival and death. When these processes are compromised, however, they can play critical roles in the pathogenesis of neurodegenerative diseases.
A genetic component is evident in many neurodegenerative diseases. Huntington's disease is a well-characterized polyglutamine disorder, in which a repeat of the CAG sequence -which encodes the amino acid glutamine -generates a polyglutamine tract. These extra glutamine residues induce irregular protein folding and alter protein function, which is toxic to the cell. Alzheimer's and Parkinson's disease also have a genetic component, with genetic analysis identifying numerous genes associated with each disorder, including ApoE4, PINK1 and LRRK2 (Table 1) . A key example of the genetic element of Alzheimer's is evident in people with Down Syndrome who have a third copy of chromosome 21. The gene that is involved in production of the toxic amyloid β plaques in Alzheimer's disease is also located on chromosome 21. People with Down Syndrome who have this extra gene copy almost universally exhibit Alzheimer's disease by 40 years of age.
Oxidative stress is another key characteristic that underlies neurodegenerative diseases. Evidence of reactive oxygen species that are toxic to cells have been described in affected brain regions of Alzheimer's and Parkinson's disease patients.
Oxidative stress not only damages cells but can trigger programmed cell death, leading to neurodegeneration. However it is unknown whether the widespread neuronal cell death seen in neurodegenerative diseases is caused by oxidative stress, or is coincident with it; therefore, strategies to therapeutically inhibit oxidative stress may help decrease cell death.
Although neurodegenerative diseases exhibit similarities in the cellular events which occur during the course of disease, there are substantive differences between each disorder which necessitate tailored therapeutic strategies. An example of where this is evident is in the effects of L-DOPA -this drug alleviates motor symptoms in Parkinson's disease yet it exacerbates motor dysfunction in Huntington's disease, despite the two diseases sharing a common cause of protein misfolding.
Disease-specific mechanisms are outlined and discussed in more detail in the following sections: Alzheimer's disease (p5), Parkinson's disease (p12) and Huntington's disease (p17).
Further work into such mechanisms may elucidate therapies to successfully target neurodegenerative diseases.
Alzheimer's Disease
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a loss of cognitive function. Neurodegeneration in the neocortex and hippocampus -regions of the brain involved in higher functions such as sensory perception, language and memory -lead to symptoms often initially associated with dementia. Indeed, AD is the most common neurodegenerative disease, accounting for 60-80% of all dementias. AD-afflicted brains exhibit an overall decrease in size (Figure 1) , and a reduction in glucose uptake that is indicative of decreased neuronal activity. Symptoms include shortterm memory loss, confusion, and irritability, which progress to long-term memory deficits and withdrawal from social interactions, followed by a loss of higher cognitive function and finally, death.
The disease was first described as presenile dementia in 1906 by German psychiatrist Alois Alzheimer. Alzheimer observed a patient with a progressive loss of cognitive function and noticed a peculiar substance in the cortex of the patient's brain postmortem. Subsequently it was discovered that these extracellular deposits, known as senile plaques, were composed of aggregated proteins called amyloid beta (Aβ). There is no cure for AD, with current therapeutic strategies only alleviating AD-associated symptoms. Drug discovery over the last 10 years has turned towards the development of disease-modifying drugs, in the hope that progression of AD can be slowed.
The causes of AD are not well defined and therefore there are several hypotheses that aim to explain the initiation and progression of the disease.
The Amyloid Hypothesis
A progressive appearance of amyloid plaques in the brain, one of the key pathological hallmarks of AD, forms the basis of the amyloid hypothesis. This hypothesis suggests that
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Figure 1 | The Alzheimer's brain
On the left is a normal healthy brain and on the right is a brain with advanced Alzheimer's disease. The Alzheimer's brain exhibits extreme shrinkage of the cerebral cortex (involved in language and emotion), severely enlarged ventricles and shrinkage of the hippocampus (involved in memory).
plaques is described throughout the normal brain with aging; in AD patients, however, it is thought that there may be more plaques concentrated in specific regions or increased plaque susceptibility.
aggregates of Aβ are the pathogenic agents in AD, which initiate harmful physiological changes leading to neurodegeneration. Amyloid plaques are dense insoluble deposits of Aβ, which are found outside neurons. An increased prevalence of (a) Amyloid precursor protein (APP) is processed by two pathways. In the non-amyloidogenic pathway: α-secretase cleaves APP within the amyloid beta (Aβ) domain, preventing Aβ formation. In the amyloidogenic pathway: β-secretase and γ-secretase release Aβ intraneuronally, before it is exported from the neuron and aggregates to form senile plaques. (b) Excessive activation of NMDA receptors leads to elevated intracellular calcium, which overloads the mitochondria, leading to cell death by excitotoxicity. (c) Hyperphosphorylation of tau generates ptau, which forms paired helical filaments (PHF) and further aggregates into neurofibrillary tangles (NFTs). (d) In tauopathies, hyperphosphorylation of tau leads to dissociation from microtubules causing them to depolymerize and breakdown, disrupting neuronal function.
Alzheimer's Disease -continued
Secretases
Aβ is the product of proteolysis of a larger transmembrane protein called amyloid precursor protein (APP). Cleavage of APP is by three enzymatic proteases: α-secretase, β-secretase, and γ-secretase. There are two potential outcomes as a result of APP cleavage. One process generates a non-toxic peptide called p3 via cleavage of APP by α-secretase and γ-secretase. Cleavage of APP by β-secretase and γ-secretase leads to the production of insoluble Aβ protein that deposits into plaques (Figure 2a ). Different fragments of Aβ can be produced; however, it is the Aβ fragment of 42 amino acids in length, known as Aβ42, that is largely found in plaques. Treating neuronal cultures with Aβ peptides such as Aβ1-42 (Cat. No. 1428) and Aβ1-40 (Cat. No. 1191) , is useful for studying the vulnerability of neurons to neurodegeneration and understanding the progression of the disease.
The proteases involved in cleavage of APP are of particular interest as they are central to the generation and modulation of the Aβ peptide and can be targeted by small compounds in vitro and in vivo. β-secretase is therefore an attractive target for the development of inhibitors to treat AD, as this protein functions at the first step in the pathway leading to production of Aβ. Despite a limited number of specific drugs for this target, EGCG (Cat. No. 4524) exhibits inhibition of both β-secretase and amyloid assembly. With γ-secretase acting as the final step in the production of Aβ, the development of γ-secretase inhibitors is seen to be a key goal in targeting build-up of toxic Aβ. First generation γ-secretase inhibitors had harmful side-effects due to off-target effects on Notch signaling. However second generation γ-secretase inhibitors, developed to be Notch-sparing -such as begacestat (Cat. No. 4283) -have shown more favorable results.
Aβ aggregation
Targeting Aβ oligomerization and aggregation is another strategy for the prevention of Aβ plaque formation. SEN 1269 (Cat. No. 4699 ) is a neuroprotective small molecule that directly binds Aβ1-42 to block Aβ aggregation and protect against Aβ1-42-induced neuronal cell death. The compound is also active in vivo, reducing the deficits in memory and LTP induced by Aβ oligomers. CGP 52411 (DAPH, Cat. No. 3360) and Ro 90-7501 (Cat. No. 2408) are both able to inhibit Aβ42 fibril formation, and therefore reduce Aβ-induced neuronal toxicity, while MRK 560 (Cat. No. 4000) attenuates Aβ plaque deposition. The neuroprotective compounds CEP 1347 (Cat. No. 4924 ) and colivelin (Cat. No. 3945) can also protect against the neurotoxic effects of Aβ. CEP 1347 is a JNK inhibitor that protects against Aβ-induced cortical neuron apoptosis, while colivelin suppresses Aβ-induced neuronal cell death and ameliorates memory impairment in AD models in vivo. The antioxidant curcumin (Cat. No. 2841) also demonstrates the ability to attenuate Aβ aggregation.
Recent evidence indicates that Aβ deposits probably precede and induce neuronal death, therefore monitoring of the pathology before clinical symptoms present would aid AD diagnosis. Fluorescent probes and dyes including: K 114 (Cat. No. 3144), a fluorescent dye that detects Aβ, α-synuclein and tau in situ; CRANAD 2 (Cat. No. 4803) a near-infrared probe that undergoes a fluorescence intensity increase upon interacting with Aβ aggregates; and methoxy-X04 (Cat. No. 4920), a probe that 
Box 1: Aβ Aggregation
A full list of targets and related products are listed on pages [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] allows the detection of plaques, tangles and cerebrovascular amyloid in situ, are all tools that will enable detection, quantification and characterization of amyloid plaques in different model systems (Box 1).
Mitochondrial dysfunction
Mitochondrial dysfunction is implicated in Aβ-induced neuronal toxicity in AD. Overproduction of mitochondrial reactive oxygen species (ROS) and increased oxidative stress is evident in the brains of AD patients. Disruption in energy metabolism, enzyme function and the mitochondrial membrane permeability transition pore (mPTP) all lead to mitochondrial dysfunction, often as a result of progressive accumulation of mitochondrial Aβ. Toxicity in the mitochondria therefore ultimately leads to cell death ( Figure 2 ). It is thought that mitochondrial dysfunction, especially that leading to compromised energy production, precedes the toxic accumulation of plaques and therefore may play an early role in the pathogenesis of AD. Methylene blue (Cat. No. 3213) , an inhibitor of tau aggregation, has also been shown to prevent mitochondrial dysfunction and targets some of the mechanisms that are impaired in AD brains, such as aerobic respiration. Dimebon (Cat. No. 3201) , which has known neuroprotectant properties against β-amyloid neurotoxicity, has also been suggested to stabilize mitochondrial function and inhibit cell death.
Tau Hypothesis
Deposition of neurofibrillary tangles composed mainly of misfolded hyperphosphorylated tau (ptau) aggregates is the second major hallmark of AD. The tau hypothesis describes the following neuropathogenesis: hyperphosphorylated tau begins to pair with other threads of tau, eventually forming neurofibrillary tangles inside neuron cell bodies. Neurofibrillary tangles are deposited in a systematic fashion, correlating closely with cognitive decline.
Tau gives structural stability to microtubules that act as dendrite scaffolding, maintaining the shape of the neuron and contact between neurons. The binding of tau to microtubules is modulated by kinases and phosphatases; phosphorylation detaches it from microtubules, which affects axonal trafficking. An imbalance between kinase and phosphatase activities results in the accumulation and aggregation of chronically hyperphosphorylated tau (Figure 2c ). Although the cause of this imbalance is unclear, several candidate enzymes have been identified that are likely to contribute to these events, some of which are discussed below.
Kinases
The abnormal phosphorylation of tau evident in AD has driven researchers to identify the kinases involved, in order to develop effective kinase inhibitors. Kinases that have been identified include glycogen synthase kinase-3 (GSK-3), dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK)1A, cyclindependent kinase 5 (cdk5), and casein kinase 1 (CK1).
Early studies demonstrated that treatment of cultured neurons with Aβ fibrils induced tau phosphorylation and that this increase was sensitive to lithium (Cat. No. 4740) , which is known to inhibit GSK-3. Inhibitors such as indirubin-3ʹoxime (Cat. No. 1813) , which inhibit GSK-3β as well as cdk5, have been shown to diminish tau phosphorylation. Maleimides such as SB 415286 (Cat. No. 1617) 
Box 2: GSK-3β
A full list of targets and related products are listed on pages [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Alzheimer's Disease -continued 1616) show selectivity for GSK-3, with the latter demonstrating an ability to reduce tau phosphorylation in postnatal rats and to reverse Aβ-induced tau phosphorylation (Box 2). Thiazoles such as AR-A 014418 (Cat. No. 3966) compete with ATP for binding to GSK-3β, and have been shown to reduce tau phosphorylation and aggregation in a mouse model of tauopathy. Upregulation of CK1 mRNA is evident in brain samples from subjects with AD. CK1 inhibitors such as D 4476 (Cat. No. 2902) cause a significant and dose-dependent reduction in Aβ40 and Aβ42 production in vitro. Additionally (R)-DRF053 (Cat. No. 3610), a dual cdk/CK1 inhibitor, has demonstrated an ability to inhibit Aβ production.
Phosphatases
Protein phosphatases catalyze the removal of phosphate groups from target proteins. Consequently, they are targets of interest with regard to the aberrantly high levels of tau phosphorylation observed in AD. The activity of the serine/threonine protein phosphates PP1, PP2A and PP5 have been shown to be decreased in AD brains. A significant amount of research has been focused on PP2A, the phosphatase thought to be mainly responsible for ptau dephosphorylation. Strategies to target dysregulation of protein phosphatase activity using compounds such as ceramide (Cat. No. 0744), a serine/threonine protein phosphatase activator, have been demonstrated to promote PP2A activity. Memantine (Cat. No. 0773) has also been reported to elevate hippocampal PP2A activity and decrease tau phosphorylation both in cells and in rat brain slices by blocking the interaction of PP2A with I2, an inhibitor binding protein. Okadaic acid (Cat. No. 1136) and calyculin A (Cat. No. 1336) are protein phosphatase inhibitors that have been suggested to have an additional role in AD, as they were able to stimulate secretion of APP.
Microtubules
As a result of the generation of hyperphosphorylated tau, accumulation of neurofibrillary tangles and microtubule instability leads to the breakdown of neuronal function (Figure 2d ). Microtubule stabilizing agents such as taxol (Cat. No. 1097) have been used to prevent breakdown in microtubules associated with tau hyperphosphorylation. Several classes of compounds have now been identified that inhibit tau aggregation and/or disassemble existing filaments in vitro. Phenothiazines, including methylene blue (Cat. No. 3213), inhibit tau filament formation and have also been reported to attenuate the rate of cognitive decline in AD patients. A new formulation of methylene blue, with higher bioavailability, is also now undergoing phase III trials. Anthraquinones, such as the chemotherapeutics daunorubicin (Cat. No. 1467) and doxorubicin (Cat. No. 2252) , have also been identified as inhibitors of tau aggregation. Alternative strategies to reduce the amount of tau in neurons involve enhancing degradation of phosphorylated tau, which has been illustrated by inhibiting heat shock protein 90 (Hsp90) using the geldanamycin derivative, 17-AAG (Cat. No. 1515 ). This reduces the burden of phosphorylated tau in affected brain regions. Interestingly, 17-AAG shows preferential affinity for complexes associated with misfolded proteins, suggesting that 17-AAG may not interfere with other physiologically important Hsp90-client protein interactions.
Cholinergic Hypothesis
The cholinergic system is a key modulator of excitatory amino acid (EAA) neurotransmission. Deficits in EAA neurotransmission are associated with a decline in learning and memory, which led researchers to postulate that the cholinergic system may play a role in the cognitive decline evident in AD. The cholinergic hypothesis of AD is one of the earliest theories; it proposes that AD is caused by deficits in the enzymes responsible for the synthesis of acetylcholine (ACh). Drugs that inhibit cholinesterases, the enzymes responsible for the breakdown of ACh in the synaptic cleft, displayed efficacy in delaying the symptoms of AD and received FDA and European approval, of which tacrine (Cat. No. 0965) was the first. However, second generation cholinesterase inhibitors including donepezil (Cat. No. 4385), rivastigmine (Cat. No. 4440) and galanthamine (Cat. No. 0686; Figure 3 ) have demonstrated a more favorable clinical profile (Box 3). Galanthamine has shown promise in treating the deficit in cholinergic signaling because of its dual effect on cholinergic synapses, both as an allosteric 
Box 3: Current Therapeutics for Alzheimer's Disease
A full list of targets and related products are listed on pages 24-33
Emerging Targets
5-HT receptors
Extensive serotonergic denervation has been observed in the AD brain and the involvement of 5-HT in both cognition and behavioral control has made its receptors an attractive target. Positive results have been noted in animal models of memory using the high affinity 5-HT 6 antagonist BGC 20-761 (Cat. No. 3326; Box 4) . Despite 5-HT receptors being unlikely to alter the progression of the disease, 5-HT 4 receptors have been suggested to play a role in the regulation of Aβ; therefore inhibitors such as GR 113808 (Cat. No. 1322) and GR 125487 (Cat. No. 1658) , which selectively target the 5-HT 4 receptor, may be useful in characterizing its role in AD.
Cannabinoid receptors
Alterations in components of the cannabinoid system have been reported in brains obtained from Alzheimer's patients. Cannabinoids are neuroprotective against excitotoxicity, and have also been shown to protect neurons from the deleterious effects of Aβ and ptau. Senile plaques in AD patients express the cannabinoid receptors CB 1 and CB 2 ; intracerebroventricular administration of synthetic cannabinoids such as WIN 55,212-2 (Cat. No. 1038), HU 210 (Cat. No. 0966; Box 4) and the CB 2 agonist JWH 133 (Cat. No. 1343) have shown potential in blocking Aβ-induced microglial activation, cognitive impairment, and loss of neuronal markers in rats.
Dual-specificity tyrosine-phosphorylation-regulated kinase
Dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK)1A overexpression has been suggested to be a significant factor leading to cognitive deficits in people with Alzheimer's disease (AD). It has been suggested that DYRK1A may provide a link between aberrant amyloid and tau pathology in AD. Dyrk inhibitors such as INDY (Cat. No. 4997; Box 4) have been shown to reverse aberrant tau-phosphorylation, with proINDY (Cat. No. 4998), a prodrug of INDY, displaying effectiveness in vivo. These recent studies suggest that DYRK1A is a promising target for AD, as investigators search for alternatives to β-secretase and γ-secretase.
Protein O-GlcNAcase
Protein O-GlcNAcase is a hydrolase involved in tau phosphoryl ation. Studies, using the selective inhibitor, thiamet G (Cat. No. 4390; Box 4), showed decreased tau phosphorylation and neuro degeneration in vivo, making protein O-GlcNAcase an emerging therapeutic target for slowing the progression of AD.
Oxidative stress
Oxidative stress is apparent in the early stages of neurodegenerative diseases, and is suggested to precede the appearance of neurofibrillary tangles in AD. Some adverse effects of Aβ potentiator of nAChRs and as an anticholinesterase. Longterm administration has recently been suggested to reduce APP deposition and neurodegeneration in a mouse model of AD, suggestive of a potential role for this target in diseasemodifying treatment. For AD sufferers, however, these drugs largely offer symptomatic relief without modifying the course of the disease.
Theory of Excitotoxicity
Glutamate-mediated neurotoxicity is a common theme in neurodegenerative diseases such as Parkinson's and Huntington's disease, and has also been implicated in the pathogenesis of AD. Excitotoxicity resulting from excessive activation of NMDA receptors has been suggested to enhance the localized vulnerability of neurons in a manner consistent with AD neuro pathology ( Figure 2b ). Attempts to develop drugs that blocked the action of glutamate were unsuccessful in the beginning, since these receptors are also required for normal brain function. It was a major breakthrough when memantine (Cat. No. 0773; Box 3) was discovered to have beneficial effects in AD, blocking excessive glutamate excitotoxicity that leads to cell death without affecting normal glutamate signaling. Memantine blocks NMDA-type glutamate receptors and represents the first in this class of AD medications.
Figure 3 | Lycoris radiata -a source of galanthamine
The red spider lily (Lycoris radiata) is a source of galanthamine, a drug currently approved for the treatment of mild to moderate Alzheimer's disease.
Disease-modifying approaches have recently become the focus of Alzheimer's disease research. Despite the prominence of particular theories on the pathogenesis of AD, there are aspects of each theory that cannot fully explain the degenerative effects of AD. Pathological targets such as the cholinesterases, amyloidogenic secretases, Aβ aggregation, and tau phosphorylation and fibrillation are the primary targets researchers are currently exploring. The hope is that new targets will be revealed that will enable identification of drugs to combat the degenerative nature of the disease. appear to be mediated by free radical formation and a resultant oxidative imbalance. Therefore, the free radical-scavenging properties of antioxidants such as vitamin E and L-ascorbic acid (Vitamin C, Cat. No. 4055) , as well as mela tonin (Cat. No. 3550) , may be beneficial in inhibiting the toxic effect of Aβ. The antioxidant coenzyme Q10 (Cat. No. 3003) has been shown to preserve mitochondrial membrane potential during oxidative stress, and protects neuronal cells by attenuating Aβ overproduction and intracellular Aβ plaque deposits.
Retinoic acid receptors
The retinoic acid receptor (RAR)α plays a key role in homeostatic control of synaptic plasticity, which is essential for memory function. It has been shown that RARα signaling is downregulated by Aβ, which inhibits the synthesis of retinoic acid. RARα signaling improves cognition and promotes Aβ clearance in Tg2576 mice (mice expressing mutant APP), as demonstrated by the use of the selective RARα agonist, AM 580 (Cat. No. 0760).
Stem cell therapy
Research into AD using stem cell therapy has been limited in comparison to Parkinson's and Huntington's disease, due to the widespread loss of neurons observed in AD. One approach is to transplant neural stem cells; however, for this cell replacement strategy to be successful, the cells would need to migrate to different areas across the brain, and differentiate into functional neuronal subtypes that establish connectivity with existing neurons. This is difficult to achieve.
Nevertheless, studies with neural stem cells (NSCs) have highlighted a neuroprotective function: NSCs improve cognition and reduce neuronal loss in vivo, without directly replacing affected neurons. These NSCs express neurotrophins that may help modulate neuronal survival. For more information on stem cell therapy for neurodegenerative disorders, see page 21.
Future Directions
Current treatments for AD alleviate the symptoms of the disease, however they do not modify its natural progression. 
Box 4: Emerging Targets for Alzheimer's Disease
A full list of targets and related products are listed on pages [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Alzheimer's Disease -continued targets, including PARP-1, 5-HT and adenosine receptors, are also under investigation.
Etiology of Parkinson's Disease
The characteristic motor symptoms of PD occur as a result of the death of dopaminergic neurons in the SNc, a constituent of the basal ganglia. The basal ganglia are a collection of nuclei within the brain (Figure 5a ) that are integral to controlling motor function, learning and cognition. In the basal ganglia of healthy subjects, a network of inhibitory and excitatory neurons regulates signal transmission through the motor thalamus to the motor cortex. Dopaminergic neurons modulate this signaling network, leading to an increase in motor activity. In PD patients the loss of dopamine neurons within the basal ganglia leads to a decrease in motor activity (Figure 5b ).
Dopamine signaling within the basal ganglia is also modulated by cholinergic interneurons within the striatum and by serotonergic neurons from the dorsal raphe nucleus (DR). As a result, both serotonergic and cholinergic neurons are also under investigation as potential non-dopaminergic targets for the treatment of PD.
Mitochondrial Dysfunction
It is thought that the selective death of dopaminergic neurons in PD is linked to an increased vulnerability of these neurons to external cell death-inducing stimuli. This is exemplified in the response of nigrostriatal dopaminergic neurons to the mitochondrial complex I inhibitor rotenone (Cat. No. 3616); although rotenone is distributed uniformly throughout the brain following administration, the development of cytoplasmic inclusions and subsequent neuronal death selectively
Introduction
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder that is principally characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). The degenerating neurons typically contain 'Lewy bod ies' and 'Lewy neurites'-the result of abnormal α-synuclein aggregation within the neuron (Figure 4 ). Together this leads to symptoms of tremor, bradykinesia, rigidity and postural instability, whilst further neurological changes trigger a number of more complex and variable non motor symptoms.
The pathogenesis of PD has been proposed to be multifactorial, with mitochondrial dysfunction, α-synuclein aggregation and proteasome dysregulation being cited as major drivers behind the loss of dopaminergic neurons in PD. Analysis of gene expression in PD patients has also revealed a genetic component of the disease, with mutations in a number of genes -including PINK1, LRRK2, DJ-1, SNCA and ATP13A2, amongst othersbeing linked to the development of PD. Proteins encoded by these genes are therefore under investigation to determine their influence on the pathogenesis of PD. Although there remains a greater proportion of sporadic cases with no obvious genetic component, analysis of these PD-associated genes has provided significant advances in understanding the pathogenesis of the disease.
In addition to targeting the underlying pathophysiological changes associated with PD, drug discovery programs also aim to develop effective therapies for the side effects of PD treatment, particularly dyskinesias invoked by L-DOPA treatment. Dopamine and glutamate receptors are long-established targets for treating L-DOPA-induced dyskinesias, while newer Under normal conditions a balance in the circuitry provides controlled movement. Dopamine secreted from neurons within the substantia nigra pars compacta (SNc) (indicated by circle arrows) modulates neurotransmission through different networks within the basal ganglia; the end result is moderation of thalamic input to the motor cortex, through excitatory and inhibitory signaling. This facilitates controlled motor activity. In PD, however, dopaminergic neurons within the substantia nigra are lost, leading to depletion of dopamine. This leads to an imbalance in these pathways, which results in decreased initiation of movement and an increased inhibition of movement, ultimately leading to decreased motor activity. Blue arrows represent the normal circuitry, with dashed orange arrows illustrating the effect of decreased dopamine input at the striatum. Thick arrows represent increased input.
affects nigrostriatal dopaminergic neurons. The experimental tool CGP 3466B (TCH 346, Cat. No. 2966 ), a GAPDH inhibitor that blocks mitochondrial complex I-mediated hydrogen peroxide release, prevents dopaminergic neuron loss in animal models of PD, demonstrating the importance of complex I as a target for PD research.
The environmental toxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) also inhibits complex I activity and can be used as a tool to induce PD-like symptoms in experimental models of the disease. MPTP itself is not toxic, but when metabolized in vivo by monoamine oxidase B (MAO-B), it forms 1-methyl-4-phenyl-pyridium (MPP + ). This toxic metabolite is concentrated in the mitochondria by the dopamine transporter, which leads to complex I inhibition, depolarization of the mitochondrial membrane and opening of the mitochondrial permeability transition pore (mPTP). MAO-B inhibitors (R)-deprenyl Complex I dysfunction in the absence of exposure to complex I inhibitors has also been observed in post-mortem studies of PD brains, suggesting that studying complex I and its downstream effects may elucidate other targets for PD research. In particular, targeting mediators of cell death which are activated following loss of complex I activity, such as Bax, AIF and cytochrome c, may uncover novel strategies for neuroprotection. Inhibitors of Bax such as Bax channel blocker (Cat. No. 2160) , Bax inhibitor peptide V5 (Cat. No. 1785) and iMAC2 (Cat. No. 3794) may be useful for studying these mechanisms. The finding that proteasome inhibitors such as MG 132 (Cat. No. 1748 ) exacerbate the toxic effects of complex I inhibition suggests that the proteasome is involved in complex I-mediated neuronal death, and that dysregulated proteasome function may also confer susceptibility to PD. Other proteasometargeting chemical tools that can be used to probe this include lactacystin (Cat. No. 2267), AM 114 (Cat. No. 2564) and PSI (Cat. No. 4045) (Box 6).
Dopaminergic neurons are particularly vulnerable to the effects of mitochondrial complex I inhibition because, unlike the majority of other neurons, they express Ca V 1.3-containing L-type calcium channels. These Ca V 1.3-containing channels exhibit an increased ATP consumption and calcium flux due to their role in pacemaking, properties which render them more susceptible to oxidative stress and cell death. The effect of this unusual property was first demonstrated in a Danish study of hypertensive patients: administration of brainpenetrant L-type calcium channel blockers such as verapamil (Cat. No. 0654), diltiazem (Cat. No. 0685) and isradipine (Cat. No. 2004 ) was associated with a significant decrease in the risk of developing PD. This effect has since been attributed to Ca V 1.3 channels, which therefore represent an attractive therapeutic target for PD.
Other mitochondrial proteins postulated to be involved in PD include PINK1, DJ-1, LRRK2 and parkin. These proteins are either located within the mitochondria or, in the case of parkin, are directly recruited by mitochondrial proteins. Mutations in the genes encoding these proteins are linked to specific forms of PD, and so are under investigation to uncover novel strategies for targeting the disease.
In particular, results of recent drug discovery programs have provided experimental tools for studying LRRK2, a protein kinase which has been implicated in both sporadic and familial PD. The most common LRRK2 mutation observed in PD is G2019S, a mutation which affects the kinase domain of LRRK2 and is thought to increase its autophosphorylation activity. LRRK2 associates with α-synuclein and this interaction has been proposed to increase the size of α-synuclein-containing intracytoplasmic inclusions. The potent and selective LRRK2 inhibitors GSK2578215A (Cat. No. 4629), LRRK2-IN-1 (Cat. No. 4273) and CZC 54252 (Cat. No. 4534) will enable further research into the function of LRRK2 and may shed light on the extent of its involvement in PD (Box 5).
Parkin, a ubiquitin ligase that is mutated in juvenile onset PD, is also a potential new therapeutic target for PD. In patients with parkin mutation-associated or sporadic PD, the parkin substrate AIMP2 accumulates in neurons, triggering PARP-1 activation. PARP-1 is a crucial component of the DNA damage No. 0529), tandospirone (Cat. No. 2854), xaliproden (Cat. No. 2491) and S 14506 (Cat. No. 1771) may enable researchers to determine the influence of 5-HT on PD.
Adenosine A 2A receptors are also a potential target for new PD therapeutics since these receptors co-localize with dopamine D 2 receptors in the striatum where they inhibit dopaminergic signaling. Inhibiting A 2A receptor activity therefore removes this effect and enhances D 2 receptor activity. This effect of normalizing dopamine signaling can be produced experimentally using A 2A antagonists such as SCH 58261 (Cat. No. 2270) , ANR 94 (Cat. No. 3937) and ZM 241385 (Cat. No. 1036) (Box 7).
α-Synuclein
Dopaminergic neurons in PD commonly contain aggregates of α-synuclein, a protein with an undetermined function that is predominantly found in neuronal tissue. The gene encoding α-synuclein, SNCA, is mutated in some forms of PD, and these mutations are thought to promote α-synuclein oligomerization and fibrillogenesis. α-synuclein has therefore been the focus of considerable PD research. A key feature of α-synuclein found within PD brains is that it is selectively and extensively phosphorylated at Ser129, a characteristic that has been shown to response, yet its excessive activation has been linked to a mechanism of cell death termed 'parthanatos.' Blocking neuronal PARP-1 activity has been proposed to counteract this pathway and may provide neuroprotection in PD. Brain penetrant PARP-1 inhibitors, including PJ 34 (Cat. No. 3255) and DR 2313 (Cat. No. 2496) may be useful tools (Box 6).
Depletion of Dopaminergic Signaling
The death of dopaminergic neurons has severe effects on motor function due to the involvement of dopamine in increasing motor activity (Figure 5b) . In order to address the decreased dopamine availability in PD, treatment has classically involved administering L-DOPA (Cat. No. 3788; Box 7), a precursor to dopamine that (unlike dopamine) can cross the blood-brain barrier. This line of treatment is still the most widely used, but its metabolism in vivo is associated with a number of unwanted side-effects including dyskinesias. L-DOPA-induced dyskinesias (LID) remains a significant problem for PD patients despite L-DOPA being accepted as a 'gold standard' for the treatment of PD. Research into alternative methods of increasing dopamine signaling in the brain may provide a replacement therapy for L-DOPA with fewer side effects.
The availability of L-DOPA is negatively affected by the activity of catechol O-methyltransferase (COMT) and dopa decarboxylase (DDC) and therefore co-administering inhibitors of these enzymes with L-DOPA is thought to increase L-DOPA's efficacy. COMT inhibitors such as entacapone (Cat. No. 4720) and OR-486 (Cat. No. 0483) prevent the conversion of the therapeutically active L-DOPA into 3-O-methyldopa, a metabolite with no therapeutic effect that competes with L-DOPA for transport into the brain. DDC inhibitors such as (S)-(-)carbidopa (Cat. No. 0455) and L-(-)-α-methyldopa (Cat. No. 0584) prevent metabolism of L-DOPA in the periphery, thereby increasing central penetration of L-DOPA.
Further strategies to compensate for the loss of dopaminergic signaling in PD include the use of post-synaptic dopamine D 2 /D 3 receptor agonists such as pramipexole (Cat. No. 4174), rotigotine (Cat. No. 3896), cabergoline (Cat. No. 2664), bromo criptine (Cat. No. 0427) and ropinirole (Cat. No. 3680) (Box 7). These mimic the effects of the depleted dopaminergic neurons within the basal ganglia and improve motor function. However, dopamine receptor agonists also exhibit undesirable side-effects including nausea, dyskinesias and hallucinations and so newer, non-dopaminergic targets are now a focus of research.
One such non-dopaminergic target under investigation is 5-HT receptors. Often implicated in the pathogenesis and treatment of mood disorders, 5-HT 1A receptors have also been linked to PD due to the involvement of serotonergic neurons in controlling motor function, and the observation that serotonergic neurons are also depleted in PD patients. Experimental tools for 5-HT receptors, in particular agonists such as 8-hydroxy-DPAT (Cat. increase α-synuclein toxicity. Kinases implicated in α-synuclein Ser129 phosphorylation include casein kinase 1 (CK1), casein kinase 2 (CK2) and GRK2, amongst others. Therefore, targeting these kinases using inhibitors such as D 4476 (Cat. No. 2902) , TBB (Cat. No. 2275) and GRK2i (Cat. No. 3594 ) blocks Ser129 phosphorylation and may retard α-synuclein-mediated cytotoxicity.
An alternative strategy for targeting α-synuclein toxicity in PD is through the promotion of α-synuclein inclusion formation. This approach, though at first paradoxical, is thought to exert a protective effect in PD by reducing the presence of toxic early aggregation intermediates such as oligomers. This can be induced experimentally using B2 (Cat. No. 2855), a neuroprotective compound that has proven effects in animal models of neurodegeneration.
Stem Cells
Neurons derived from stem cells have been used for drug screening and cell replacement therapy in neurodegenerative disorders including PD. In addition, the pathogenesis of PD may be modeled using stem cell-derived neurons.
PD has been a focus of significant stem cell research, due to the fact that a specific type of neuron and discrete brain region are involved. Previously, dopaminergic neuroblasts could be replaced by transplant of human embryonic mesencephalic tissue, a source rich in these cells. These grafts served as proof of principle that cell replacement therapy could be an effective way to treat PD in humans. Building upon this idea, pluripotent stem cells may also be directed to differentiate into dopaminergic neuroblasts for cell therapy, constituting a standardized source of cell material. For more information on stem cell therapy for neurodegenerative disorders, see page 21.
Future Directions
The identification of multiple gene mutations associated with PD has provided a new set of molecular targets for the focus of future PD research, whilst further genetic analysis may uncover additional molecular targets involved in PD. The availability of potent and selective tool compounds, such as LRRK2 inhibitors, will enable researchers to elucidate the contribution of these individual proteins to the pathogenesis of PD and may lead to an efficacious therapy to replace the current gold standard, L-DOPA. Combinatorial therapy, such as the co-administration of dopamine receptor partial agonists with 5-HT agonists, may also represent a beneficial strategy for targeting the multi-faceted nature of PD and may lead researchers to achieve the ultimate goal: an efficacious therapy for PD. Huntington's Disease
Introduction
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease. It is characterized by mental decline, psychiatric disorder and motor dysfunction -predominantly chorea, an involuntary movement disorder. These symptoms are thought to result from the cellular aggregation and activity of mutant huntingtin protein in the cytoplasm and nuclei of neurons. Although huntingtin protein (Htt) is expressed throughout the central nervous system, medium spiny neurons (MSNs) in the basal ganglia of the striatum exhibit particular vulnerability to neurodegeneration in HD. There are no disease-modifying therapies currently available for HD; the only currently FDA-approved drug for HD is tetrabenazine (Cat. No. 2175), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2). Current research is focused on the identification of new therapeutic targets, some of which are described below.
Etiology of Huntington's Disease
Htt is a predominantly cytoplasmic protein that is vital for embryogenesis and development. It has been linked to a variety of processes, including protein trafficking and vesicle transport; a potential role as a scaffold protein therefore seems likely. Htt is encoded by the IT15 gene, in which the unstable expansion of a three base sequence (CAG, encoding glutamine) in exon 1 results in the generation of a protein with an elongated stretch of glutamine residues (a polyglutamine (polyQ) tract) at its amino terminus. If more than 35 CAG repeats are present, the protein expressed (mutant huntingtin, mHtt) has different characteristics to the normal protein product. Both mutant and wild-type (wt) alleles are expressed in HD; if more than 40 CAG repeats are present in an allele, it is genetically penetrant. Domains containing multiple glutamine residues are often involved in the mediation of protein-protein interactions, and necessitate a certain degree of inherent conformational flexibility. Mutations affecting this region are thought to affect this flexibility and thus protein activity. mHtt, and fragments of it, initiate both deleterious as well as compensatory processes that leave affected neurons more susceptible to general injury, such as oxidative and excitotoxic stressors.
Numerous transgenic in vivo and in vitro models have been generated to examine the pathology and behavioral phenotypes of HD, with particular focus on motor deficits, intra nuclear inclusions, transcriptional dysregulation, mitochondrial dysfunction and excitotoxicity. Using these models as a basis for research into the mechanisms underlying the motor and nonmotor symptoms of HD has proven fruitful; current treatments for HD are, however, unable to offset the progression of the disorder. Nevertheless, treatment of the movement and behavioral disorders associated with HD may mitigate disease symptoms, while regenerative therapies could replace damaged neurons. For a summary of therapeutic interventions in HD, see Figure 6 .
Proteolysis and Inclusion Bodies
Inclusion bodies are a pathological hallmark of HD, and are usually observed in cells where mHtt is expressed. They are formed of protein aggregates containing toxic N-terminal mHtt fragments, which are generated by the caspase, calpain and matrix metalloproteinase (MMP) enzymes that are expressed in MSNs. Aggregates also include numerous sequestered proteins, including ubiquitin and chaperone proteins. Nuclear aggregates consist mainly of the toxic mHtt fragments, while cytoplasmic inclusions contain both full length and truncated mHtt. It is not entirely known if inclusion bodies merely coincide with disease, or if they themselves are cytotoxic; several lines of evidence suggest that by sequestering diffuse mHtt fragments, inclusions prolong cell survival. For example, the small molecule B2 (Cat. No. 2855) has been shown to promote inclusion formation, whilst also preventing mHtt-mediated proteasome dysfunction in a cellular HD model. B2-induced inclusion formation also reduces α-synuclein toxicity in Parkinson's disease (PD). Greater understanding of the mechanisms behind mHtt processing and inclusion body formation may therefore help elucidate disease progression.
It has also been suggested that the presence of cellular aggregates stimulates autophagy. Conversely, inhibition of autophagy increases aggregate formation and soluble mHtt levels.
Products by Category Page
Adenosine A 2A Receptors .................................................... 24  Antidepressants and SSRIs ................................................. 25  Antioxidants ........................................................................... 25  Atypical Antipsychotics ....................................................... 26  Autophagy ............................................................................... 26  Deacetylases ..................................................................... 
.-
Figure 6 | Therapeutic interventions in Huntington's disease
Huntingtin protein synthesis and processing is integral to HD pathology. mHtt is generated by translation of an allele containing over 35 CAG repeats. It is processed by proteolytic enzymes (namely calpains, caspases and MMPs) to generate toxic N-terminal fragments. These fragments form inclusion bodies in the cytoplasm and nucleus of the neuron, a key hallmark of HD pathology. The interactions of mHtt with a variety of cellular processes and proteins has resulted in the identification of numerous therapeutic targets; a range of small molecules acting at these targets exhibit beneficial effects in transgenic HD models. These include: antioxidants; calcium signaling inhibitors; protease inhibitors; autophagy activators; SIRT1 inhibitors; inducers of heat shock response; histone deacetylase (HDAC) inhibitors; promoters of inclusion formation; and finally, small interfering RNA (siRNA) (examples shown in green). Small molecules have also been used to generate toxin models of HD (examples shown in red). Abbreviations: 3-NP -3-Nitropropionic acid; BDNF -brain-derived neurotrophic factor; Hsp40 -heat shock protein 40; Hsp70 -heat shock protein 70; IP 3 R -IP 3 receptor; MMPs -matrix metalloproteinases; NMDAR -NMDA receptor; QA -quinolinic acid; ROS -reactive oxygen species; UPS -ubiquitin-proteasome system; VGCC -voltage-gated calcium channel.
A variety of autophagy-inducing compounds have shown efficacy in HD models: rapamycin (Cat. No. 1292) inhibits mTOR, a negative regulator of autophagy that is also sequestered into aggregates. Rapamycin has been shown to lower Htt accumulation in cell models; it also protects against neurodegeneration in a fly model of HD. SMER 28 (Cat. No. 4297) increases autophagosome synthesis and enhances the clearance of mHtt in mammalian cells. Additionally, the Ca 2+ channel blocker and autophagy activator, verapamil (Cat. No. 0654), exhibits neuroprotective properties in various HD models. The deacetylase sirtuin 1 (SIRT1) prevents autophagic degradation of Htt by removing its acetyl tags. Selective SIRT1 inhibitors, such as EX 527 (selisistat, Cat. No. 2780), may therefore aid Htt degra dation via autophagy and increase its clearance. However, deacetylation of regulatory transcription factors by SIRT1 also promotes the expression of neuroprotective genes and brain-derived neurotrophic factor (BDNF). 
Box 8: Proteolysis
A full list of targets and related products are listed on pages [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Transcriptional dysregulation affects levels of BDNF (Cat. No. 2837 ) and its receptor, TrkB, both of which are often downregulated in HD. Reducing BDNF production increases neuronal loss, so restoring it to normal levels could aid the survival of striatal neurons. Increasing BDNF levels by upstream and downstream pathways may be therapeutically viable options. Infusion of recombinant BDNF, use of cell grafts releasing BDNF, and BDNF mimetics are all potential strategies currently undergoing basic research. TrkB receptors may be transactivated by adenosine A 2A receptors; inhibition of the latter, by compounds such as SCH 58261 (Cat. No. 2270) , is neuroprotective in excitotoxic models of HD, suggestive of a role for TrkB in excitotoxicity.
Mitochondrial Dysfunction
Neurons generally require high levels of ATP to maintain functions such as membrane polarization and vesicle trafficking. MSNs in particular require a lot of energy from oxidative phosphorylation, and so are especially sensitive to the mitochondrial dysfunction that is often evident in HD models. mHtt associates with the outer membrane of mitochondria, resulting in an impairment of the electron transport chain complexes II and III. Succinate dehydrogenase (mitochondrial complex II), can be targeted by the compounds 3-Nitropropionic acid Cat. No. 4849) and methylmalonate (Cat. No. 4979 ); 3-NP generates HD disease-like pathology, while methylmalonate induces neuronal cell death. Impaired mitochondrial function has also been correlated with increased activity of the enzyme transglutaminase 2 (TG2). TG2 accumulates in cells under stress, and is upregulated in animal models of HD. Its deletion in two HD mouse models improved survival mHtt is subject to misfolding due to its abnormally long polyglutamine tract. Chaperone proteins are of interest in HD research, since they re-fold misfolded proteins and can suppress the generation of polyglutamine oligomers that later form aggregates. Chaperones are also known as heat shock proteins, of which three are of significance in HD: Hsp90, Hsp70 and Hsp40. Hsp70 and Hsp40 have been shown to attenuate the formation of fibrils by polyglutamine proteins, while Hsp90 counts Htt and mHtt amongst its client proteins. Inhibition of Hsp90 destabilizes huntingtin, aiding its clearance by the ubiquitin-proteasome system (UPS). Hsp90 inhibition, by compounds such as geldanamycin (Cat. No. 1368) , also induces the expression of Hsp70 and Hsp40, inhibiting mHtt aggregation by activating a heat shock response. Celastrol (Cat. No. 3203) also induces a heat shock response and has been identified in various screens for Htt aggregation. Additional Hsp90 inhibitors, such as PU H71 (Cat. No. 3104) and BIIB 021 (Cat. No. 4608 ) may also be useful tools (Box 8).
Transcriptional Dysregulation
mHtt and its fragments can bind directly to transcription factors, altering gene expression. Intranuclear aggregates containing mHtt sequester CBP (CREB-binding protein), the protein that binds CREB (cyclic AMP response elementbinding protein). mHtt binds to the acetyltransferase domain of CBP, alongside the co-activator p300. The resulting reduction in acetyltransferase activity can be countered by use of histone deacetylase (HDAC) inhibitors; sodium butyrate (Cat. No. 3850) improves survival, while brain-penetrant SAHA (Cat. No. 4652) attenuates motor deficits in HD mouse models.
Huntington's Disease -continued 
Box 9: Excitotoxicity
A full list of targets and related products are listed on pages [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and reduced neuronal death. Pharmacological inhibition of TG2 reverses susceptibility of human HD cells to 3-NP, and also mitigates transcriptional dysregulation. Cystamine (Cat. No. 4981 ) is a transglutaminase inhibitor that also increases BDNF secretion (and thus endogenous BDNF levels). It has been shown to improve motor performance and prolong survival in HD mice.
Mitochondria are closely linked to the production of reactive oxygen species (ROS). Excess levels of ROS result in oxidative stress, which is elevated in HD cells. Antioxidants have subsequently been the subject of HD trials; Nrf2, a transcription factor involved in the antioxidant response, and which is activated by stress, is also neuroprotective in an HD model. Nrf2 reduces the mean lifetime of polypeptides containing a polyQ expansion, and also increases neuronal survival in vitro. Consequently, Nrf2 is a key contributor to mHtt clearance, and activators of Nrf2, such as TAT 14 (Cat. No. 4811) , DMF (Cat. No. 4512) and MMF (Cat. No. 4511) may be useful tools.
Excitotoxicity
Glutamate
As discussed above, HD primarily affects striatal MSNs, a popu lation of neurons that receives both glutamate signals from the cortex and dopamine signals from the substantia nigra. A long-standing hypothesis postulates that high levels of excitatory neurotransmitters and/or activation of postsynaptic glutamate receptors (in particular the NMDA receptor) on MSN membranes sensitizes them to excitotoxic cell death. The combination of numerous glutamatergic afferents and unique NMDA receptor subtype composition (NR1A and NR2B) in MSNs could make them vulnerable to injury in HD. Since MSNs are GABAergic, the loss of their inhibitory input to the globus pallidus is thought to underlie the choreic movements characteristic of HD.
mHtt is believed to enhance the activity of NMDA receptors, and NR1A and NR2B are particularly susceptible to an increase in current flow mediated by mHtt. Agonists and antagonists of NMDA receptors have been utilized widely in basic HD research. Quinolinic acid (Cat. No. 0225) , an endogenous NMDA receptor agonist, is often used to generate HD models, while the NMDA receptor antagonist (+)-MK-801 (Cat. No. 0924) has been shown to prevent neuronal cell loss induced by mitochondrial toxins. Dimebon (Cat. No. 3201) exhibits affinity for NMDA receptors, and displays neuroprotective effects in HD cellular models, but is no longer under clinical development for HD therapy (Box 9).
Rate of glutamate uptake has been shown to be inversely related to the number of CAG repeats; rate of glutamate uptake, and therefore clearance from the synaptic cleft, is low in HD brain tissues. The expression and function of the rodent glutamate transporter GLT-1 (ortholog of EAAT2) is decreased by mHtt. Increasing glutamate uptake or inhibiting its release may therefore be advantageous. The anticonvulsant lamotrigine (Cat. No. 1611) inhibits glutamate release and may slow the progression of HD. However, the glutamate release inhibitor riluzole (Cat. No. 0768) showed no beneficial effects in a phase III HD trial.
Dopamine
Dopamine is thought to act synergistically with glutamate to increase Ca 2+ levels, sensitizing striatal neurons to mHtt toxicity and inducing apoptosis in MSNs. High doses of dopamine can also induce cell death of striatal neurons, likely via oxidative stress. Administration of the dopamine precursor L-DOPA (Cat. No. 3788) consistently elevates dopamine levels and increases loss of MSNs in HD mice, as well as worsening dyskinetic symptoms in HD patients. Conversely, L-DOPA has a beneficial effect in PD patients, restoring motor function by elevating dopamine concentrations that are affected by degeneration of the substantia nigra. Motor dysfunction and MSN loss is also evident in dopamine transporter knockout mice, which have consistently high dopamine levels.
Dopamine 'stabilizers', such as pridopidine and OSU-6162 (Cat. No. 2599) , have been shown to decrease locomotor activity when dopamine levels are high, in animal models. Both bind and rapidly dissociate from dopamine D 2 receptors, which, alongside D 1 receptors, are widely expressed in MSNs. Recent research has suggested that the effects of these compounds may also be mediated by σ 1 receptors, for which they display nanomolar affinity in vitro. Tetrabenazine (Cat. No. 2175) , the reversible VMAT2 inhibitor, is believed to improve motor function by depleting dopamine storage vesicles, but exhibits some serious side-effects, including depression due to lowered serotonin levels. Another VMAT2 inhibitor, reserpine (Cat. No. 2742) , also depletes dopamine stores, but exhibits irreversible binding and is more toxic.
Stem Cells
Stem cells have applications in a variety of diseases, not least neurodegenerative disorders. Three major types of stem cell exist: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells, the latter of which includes mesenchymal, hematopoietic and neural stem cells. With regard to HD research, iPSCs hold a great deal of interest, due to the fact that they can be derived from easily obtained somatic cells that contain the disease mutation. Consequently, they provide researchers with a source of cells for drug screening, disease modeling and cell replacement therapy, following directed differentiation into the cell type of interest (e.g. medium spiny neurons).
Neuronal differentiation of stem cells can be achieved with a range of small molecules (Box 10). The synthetic retinoid EC 23 (Cat. No. 4011 ) and GSK-3β inhibitor TWS 119 (Cat. No. 3835) can both induce neuronal differentiation in ESCs, while the γ-secretase inhibitor DAPT (Cat. No. 2634) induces neuronal differentiation from ESC-derived embryoid bodies. SAG (Cat. No. 4366 ) is a hedgehog signaling activator that induces the differentiation of dopaminergic neurons from iPSCs. Other compounds include ISX 9 (Cat. No. 4439), which enhances NeuroD1 expression to induce cortical neuron differentiation, and metformin (Cat. No. 2864) , which promotes neurogenesis from neural precursors. Thus, different stem and progenitor cells can be coaxed into specific cell types for regenerative therapy. Recent research has generated replacement MSNs from neural stem cells by use of BDNF and noggin proteins. Transplantation of ESC-derived GABA neurons was shown to correct motor problems in quinolinic acid-lesioned mice, while transplantation of human adipose-derived stem cells was also shown to reduce loss of striatal neurons and lower the number of Htt aggregates in a quinolinic acid-lesioned rat model. The blueberry fruit (Vaccinium corymbosum) is a source of the antioxidant fisetin, an ERK activator that has been shown to improve survival in cells expressing mHtt.
by increasing neuronal differentiation of proliferating cells. Sertraline (Cat. No. 2395) also promotes neurogenesis and raises BDNF levels in R6/2 transgenic mice.
Future Directions
While no current treatments stop or reverse the progression of HD, it is hoped that the discovery and/or elucidation of potential drug targets may help drive the development of disease-modifying therapies. In spite of similar neurodegenerative mechanisms, HD differs from AD and PD by virtue of the fact that it is a purely genetic disorder. As a result of this, gene silencing is undergoing research in HD mouse models, with small interfering RNAs (siRNAs) and antisense oligonucleotides being used to selectively target the messenger RNA (mRNA) encoded by the mutant allele. Clinical trials in HD patients using this approach are on the horizon. As with other neuro degenerative diseases, stem cells may also be of future benefit; they can be coaxed into specific cell types for regenerative therapy, ideally replacing the lost neurons and restoring normal brain function. Fundamental questions regarding the roles of Htt and its interactions with intracellular proteins have yet to be answered, but it is hoped that research into Huntington's disease may help inform research into other neurodegenerative disorders with similar pathologies.
While ex vivo techniques (i.e. drug screening) may be readily achievable, the transplantation of modified cells into humans is subject to great scrutiny and legislation, since the safety of such therapies is not entirely known. Likewise, the function and integration of these cells would need to be assessed. Nevertheless, stem cells provide a viable alternative to animal or in vitro models of HD, which do not always recapitulate the disease characteristics accurately.
Additional Targets
Kynurenine monooxygenase
The enzyme kynurenine 3-monooxygenase (KMO, also known as kynurenine 3-hydroxylase) is involved in tryptophan metabolism. Metabolites in the kynurenine pathway, generated by tryptophan degradation, have been linked to HD; excitotoxicity and free radical generation are associated with low levels of kynurenic acid. The KMO inhibitor Ro 61-8048 (Cat. No. 3254) increases levels of kynurenic acid, lowering levels of extracellular glutamate and preventing synaptic loss in a mouse model of HD. Increased concentrations of kynurenic acid also antagonize the glycine site of NMDA receptors.
ERK pathway
The antioxidants fisetin (Cat. No. 5016, Figure 7 ) and resveratrol (Cat. No. 1418) , have been shown to improve cell survival and exhibit neuroprotective activity, respectively, in two different HD models. This activity is thought to result from the activation of ERK by these two compounds. Fisetin has also been shown to reduce neurodegeneration in flies, and increase median lifespan of flies and mice expressing mHtt.
In addition, ERK may be activated by TrkB receptors, following BDNF binding. In Drosophila glial cells, mHtt inhibits ERKdependent expression of glutamate transporters, which could contribute to excitotoxicity. ERK inhibitors, such as FR 180204 (Cat. No. 3706) and TCS ERK 11e (Cat. No. 4465) may therefore be useful tools for studying the role of ERK in HD pathology.
Psychiatric symptoms
Antidepressants (mainly selective serotonin reuptake inhibitors, SSRIs) and antipsychotics may also be used to counter the psychiatric manifestations of HD. SSRIs such as citalopram (Cat. No. 1427) increase serotonin levels by preventing its reuptake into presynaptic cells; by doing so, they raise BDNF levels. Certain SSRIs have also been shown to increase neurogenesis, motor control and cognitive ability in mouse HD models. For example, paroxetine (Cat. No. 2141) attenuates motor dysfunction and increases survival in HD mice; fluoxetine (Cat. No. 0927) has been shown to improve cognitive function in transgenic HD mice, as well as improving neurogenesis 
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